Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys Could Earn Up to $24M in New Roche Pact

NEW YORK, March 1 (GenomeWeb News) - Roche and MorphoSys, a German synthetic antibodies producer, have expanded their six-year partnership to develop therapeutic antibodies in oncology, the companies said today.


The firms will collaborate on two new antibody programs in oncology, from which MorphoSys will receive an upfront payment and may receive additional research funding and future event payments totaling more than €10 million ($11.9 million) per program, plus potential royalties, according to the companies.


The companies also said that Roche will be responsible for preclinical and clinical development as well as subsequent marketing of all resulting products.


The new agreement is expanded from a collaboration on Alzheimer's disease that Roche and MorphoSys began in 2000.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.